Literature DB >> 34223793

Hsa_circ_0008360 sponges miR-186-5p to target CCND2 to modulate high glucose-induced vascular endothelial dysfunction.

Qian-Qian Zhu1, Xi-Bin Pu1, Tian-Chi Chen1, Chen-Yang Qiu1, Zi-Heng Wu1, Lu Tian1, Yang-Yan He1, Xiao-Hui Wang1, Tao Shang1, Xun Wang1, Yi-Lang Xiang1, Dong-Lin Li1, Hong-Kun Zhang1.   

Abstract

Vascular endothelial dysfunction is associated with the progress of many diseases. Circular RNAs (circRNAs) take part in the dysfunction of vascular endothelium. CircRNA hsa_circ_0008360 (circ_0008360) is dysregulated in high glucose-treated vascular endothelium, while the role and mechanism of circ_0008360 in high glucose-induced dysfunction remain unknown. Human umbilical vascular endothelium cells (HUVEC) were stimulated via high glucose. The abundances of circ_0008360, miR-186-5p and cyclin D2 (CCND2) were examined via quantitative real-time polymerase chain reaction or western blot. Vascular endothelial dysfunction was assessed via cell viability, apoptosis, migration and tube formation. The target relationship between miR-186-5p and circ_0008360 or CCND2 was analyzed via dual-luciferase reporter, RNA pull-down and RNA immunoprecipitation analyses. Circ_0008360 expression was enhanced in high-glucose-treated HUVEC. Circ_0008360 silence mitigated high glucose-induced suppression of viability, migration, tube formation, and increase in apoptosis in HUVEC. MiR-186-5p was sponged by circ_0008360, and miR-186-5p inhibition reversed the effect of circ_0008360 silence on high glucose-induced vascular endothelial dysfunction. MiR-186-5p alleviated high glucose-induced vascular endothelial dysfunction via targeting CCND2. CCND2 interference abolished the aggravated effect of circ_0008360 on high glucose-induced vascular endothelial dysfunction. Circ_0008360 knockdown attenuated high glucose-induced vascular endothelial dysfunction via regulating miR-186-5p and CCND2, indicating circ_0008360 might act as a target for the treatment of vascular endothelial dysfunction.Abbreviations: circRNAs, circular RNAs; HUVEC, human umbilical vascular endothelium cells; CCND2, cyclin D2; XPNPEP3, X-prolyl aminopeptidase 3; ceRNAs, competing endogenous RNAs; miRNAs, microRNAs; qRT-PCR, quantitative real-time polymerase chain reaction; RIP, RNA immunoprecipitation; HIF-1α, hypoxia inducible factor 1 alpha; TLR3, toll-like receptor 3; AKAP12, A-Kinase Anchoring Protein 12; ox-LDL, oxidized low-density lipoprotein; HG, high glucose; NG, normal glucose.

Entities:  

Keywords:  CCND2; Vascular endothelial dysfunction; circ_0008360; high glucose; miR-186-5p

Mesh:

Substances:

Year:  2021        PMID: 34223793      PMCID: PMC8344795          DOI: 10.1080/15384101.2021.1918877

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  37 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Low expression of miR-186-5p regulates cell apoptosis by targeting toll-like receptor 3 in high glucose-induced cardiomyocytes.

Authors:  Ye Liu; Wei Zheng; Yue Pan; Jing Hu
Journal:  J Cell Biochem       Date:  2018-12-03       Impact factor: 4.429

Review 3.  High glucose-induced endothelial progenitor cell dysfunction.

Authors:  Hongyan Kang; Xuejiao Ma; Jiajia Liu; Yubo Fan; Xiaoyan Deng
Journal:  Diab Vasc Dis Res       Date:  2017-07-18       Impact factor: 3.291

Review 4.  Circular RNAs function as ceRNAs to regulate and control human cancer progression.

Authors:  Yaxian Zhong; Yajun Du; Xue Yang; Yongzhen Mo; Chunmei Fan; Fang Xiong; Daixi Ren; Xin Ye; Chunwei Li; Yumin Wang; Fang Wei; Can Guo; Xu Wu; Xiaoling Li; Yong Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2018-04-07       Impact factor: 27.401

Review 5.  Endothelial cells: source, barrier, and target of defensive mediators.

Authors:  Lubka T Roumenina; Julie Rayes; Marie Frimat; Veronique Fremeaux-Bacchi
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

Review 6.  Diabetes and Vascular Disease: Is It All About Glycemia?

Authors:  Alessandra Vecchié; Fabrizio Montecucco; Federico Carbone; Franco Dallegri; Aldo Bonaventura
Journal:  Curr Pharm Des       Date:  2019       Impact factor: 3.116

7.  Alterations of circular RNAs in hyperglycemic human endothelial cells.

Authors:  Fei-Fei Shang; Suxin Luo; Xiaoxue Liang; Yong Xia
Journal:  Biochem Biophys Res Commun       Date:  2018-03-30       Impact factor: 3.575

Review 8.  MicroRNAs as pharmacological targets in endothelial cell function and dysfunction.

Authors:  Aránzazu Chamorro-Jorganes; Elisa Araldi; Yajaira Suárez
Journal:  Pharmacol Res       Date:  2013-04-18       Impact factor: 7.658

9.  Profiling and functional analysis of differentially expressed circular RNAs in high glucose-induced human umbilical vein endothelial cells.

Authors:  Guoxi Jin; Qiong Wang; Xiaolei Hu; Xiaoli Li; Xiaoyan Pei; Erqin Xu; Minglong Li
Journal:  FEBS Open Bio       Date:  2019-08-22       Impact factor: 2.693

10.  Downregulation of circRNA DMNT3B contributes to diabetic retinal vascular dysfunction through targeting miR-20b-5p and BAMBI.

Authors:  Ke Zhu; Xin Hu; Han Chen; Fang Li; Ning Yin; Ai-Lin Liu; Kun Shan; Yao-Wu Qin; Xin Huang; Qing Chang; Ge-Zhi Xu; Zhongfeng Wang
Journal:  EBioMedicine       Date:  2019-10-19       Impact factor: 8.143

View more
  2 in total

Review 1.  Promising Strategies for Preserving Adult Endothelium Health and Reversing Its Dysfunction: From Liquid Biopsy to New Omics Technologies and Noninvasive Circulating Biomarkers.

Authors:  Carmela Rita Balistreri
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

2.  circ‑Grm1 promotes pulmonary artery smooth muscle cell proliferation and migration via suppression of GRM1 expression by FUS.

Authors:  Shijing Sun; Qingyu Kong; Zhifeng Cai; Minmin Wang; Haizhao Zhao; Cuifen Zhao
Journal:  Int J Mol Med       Date:  2021-09-16       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.